Patients in the early stages of psychosis respond to treatments differently than those who have developed a chronic version of the disorder. Understanding the neurobiological changes from early to chronic stages is essential for developing targeted prevention and treatment strategies. But how symptoms change during this transition—and what role the brain plays—is unclear.

Researchers at Yale School of Medicine (YSM) have now examined patients with early and chronic forms of psychosis to map symptom evolution and identify relevant brain networks. They published their findings in the journal Neuropsychopharmacology.

“We are interested in how psychosis and psychiatric disorders develop,” says Maya Foster, first author of the study and a Ph.D. student in the lab of Dustin Scheinost, Ph.D., associate professor of radiology and biomedical imaging at YSM.